The Genomics Market is projected to reach $72.62 billion by 2030, at a CAGR of 18.2% from 2023 to 2030. Genomics studies the structure, function, evolution, and mapping of genomes. It involves several operations, from sequencing to analysis, to understand the genetic basis of various biological phenomena. Genomics can be applied to various fields, including medicine, agriculture, biotechnology, and ecology, and is critical for understanding the complexity of living organisms. By understanding the genetic makeup of an organism, researchers can develop targeted therapies, design new crops and livestock, and gain insights into evolutionary history and ecological interactions.
Funding and investment from private and public organizations, the falling cost of sequencing, and the high prevalence of genetic diseases are the factors driving the growth of this market. Additionally, the rising adoption of personalized medicine and gene therapy is expected to provide significant growth opportunities for the market’s growth.
However, the shortage of skilled professionals in bioinformatics and genomics and the challenges related to the commercialization and scaling of genomic technologies are expected to hamper the growth of the genomics market.
The costs of DNA sequencing influence the trends in genetic testing. Earlier, despite the awareness regarding genetic testing, the high cost of kits and instruments restricted access to genetic tests. However, in recent years, the emergence of advanced NGS technologies has lowered sequencing costs and significantly reduced the time required for DNA sequencing. In the U.S., according to the National Human Genome Research Institute (NHGRI), the cost of sequencing a human genome decreased from USD 29,092 in 2010 to USD 562 in 2021. Earlier, DNA sequencing was performed using the Sanger sequencing method, costing around USD 500 per 1,000 bases. However, sequencing platforms have advanced, leading to a huge reduction in sequencing costs. For instance, advanced Next Generation Sequencing (NGS) costs less than USD 0.50 per 1,000 bases.
This huge cost difference is attributed to the advantages of NGS, including higher sensitivity in detecting low-frequency variants, faster turnaround times for high sample volumes, higher capacity with sample multiplexing, a lower detection limit, and the ability to sequence thousands of genes or gene regions simultaneously. The reduced process time and lower reagent and manpower requirements of NGS also contribute to cost reduction. Furthermore, targeted genomic sequencing approaches are being used to identify specific genes. Tests can be performed to search for specific traits or gene errors instead of sequencing the entire genome. Thus, the decreasing costs of sequencing procedures are making genetic testing more affordable, driving the market’s growth.
Click here to: Get Free Sample Pages of this Report
Funding and Investment from Private and Public Organizations Driving the Market’s Growth
There has been a significant increase in funding for genomics research due to various research activities, which has led to the development of advanced sequencing technologies and bioinformatics tools that have made it possible to analyze vast amounts of genomic data. Pharmaceutical companies are investing in genomics research to discover new drugs, develop personalized medicine, and improve their understanding of disease mechanisms. The pharmaceutical industry is also investing in genomic data-sharing initiatives to accelerate research and development. In December 2022, the U.K. government announced funding of USD 217 million (GBP 175 million) for genomics research. It includes USD 130 million (GBP 105 million) to boost the diagnosis of rare genetic diseases in newborns.
The availability of genomic data has also opened opportunities for developing targeted therapies and precision medicine and has enabled researchers to understand the genetic basis of diseases, develop new diagnostics, and find potential targets for drug development. The growing investment in genomics research is expected to lead to significant medical advancements, including new drugs, targeted therapies, and personalized medicine.
Based on Offering, in 2023, the Consumables Segment is Expected to Account for the Largest Share of the Market
The large market share of this segment can be attributed to the growing adoption of genetic testing and increased usage of consumables for the same. The demand for high-throughput sequencing and automation has risen in recent years, leading to an increase in the rate of sample preparation and quality control procedures. Furthermore, it has resulted in higher consumption of consumables such as kits and reagents. The recurring purchase of consumables over instruments also contributes to the substantial market share of this segment.
Based on Technology, in 2023, the Sequencing Segment is Expected to Account for the Largest Share of the Market
The factors contributing to the large market share of this segment are technological advancements in sequencing, improvements in the efficiency of the sequencing process, and increased scalability. With the development of new sequencing technologies, the cost of sequencing has significantly decreased, and the speed and accuracy of sequencing have improved. These factors have made sequencing more accessible and cost-effective, allowing researchers to sequence more genomes.
Based on Application, in 2023, the Drug Discovery & Development Segment is Expected to Account for the Largest Share of the Market
The large market share of this segment is attributed to the high prevalence of chronic diseases such as diabetes and cancer and the need to discover effective drug therapy against these diseases. The use of genomic technologies in the field of precision medicine is rising, especially for the discovery of novel therapeutics. As precision medicine continues to gain momentum, pharmaceutical companies are increasingly investing in genomics to advance their drug discovery and development efforts.
Based on End User, in 2023, the Pharmaceutical & Biotechnology Companies Segment is Expected to Account for the Largest Share of the Market
The large market share of this segment can be attributed to the multiple benefits of using genomics in drug discovery and development. Genomics has been instrumental in identifying potential targets, reducing errors in clinical trials, and accelerating the time taken to bring new drugs to the market. Moreover, the use of genomics in personalized medicine is also increasing, as it allows for a more targeted approach to drug development by identifying specific genetic targets for new therapies. This approach can lead to the development of more effective drugs with fewer side effects.
In addition, the integration of sophisticated data analysis tools and techniques with genomics has enabled researchers to mine large datasets for insights into disease biology and drug discovery. This has further increased the adoption of genomic technologies, especially among pharmaceutical and biotechnology companies.
North America: Expected to be the Largest Regional Market in 2023
North America’s major market share can be attributed to the increasing cases of genetic diseases, growing awareness about early genetic disease diagnosis, governments promoting certain genetic testing in case of hereditary cancers and newborn screening, and the presence of major market players. Additionally, favorable government support and initiatives to increase genetic testing in prenatal, hereditary, and multifactorial conditions drive the growth of this regional market.
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in this market in the last three to four years. The key players profiled in the global genomics market report are Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Illumina, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), New England Biolabs, Inc. (U.S.), Promega Corporation (U.S.), and QIAGEN N.V. (Netherlands).
Scope of the Report:
Genomics Market Assessment, by Offering
Genomics Market Assessment, by Technology
Genomics Market Assessment, by Application
Genomics Market Assessment, by End User
Genomics Market Assessment, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the genomics market, including the market sizes & forecasts for various segmentation such as offering, technology, application, end user, and geography. This report also involves the value analysis of various segments and subsegments of the genomics market at the regional and country levels.
The global genomics market is projected to reach $72.62 billion by 2030, at a CAGR of 18.2% during the forecast period.
In 2023, the consumables segment is expected to account for the largest share of the market due to the high demand for consumables from the increasing number of genetic testing and quality control processes.
In 2023, the pharmaceutical & biotechnology companies segment is expected to account for the largest market share due to the increased use of genomics in targeted drug development, biomarker discovery, and data analysis
The growth of this market can be attributed to funding and investments from private and public organizations, a decline in sequencing costs, and an increase in the prevalence of genetic diseases. Additionally, the rising adoption of personalized medicine and gene therapy is expected to provide significant growth opportunities for the market’s growth.
The key players profiled in the global genomics market report are Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Illumina, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), New England Biolabs, Inc. (U.S.), Promega Corporation (U.S.), and QIAGEN N.V. (Netherlands).
Emerging economies in the Asia-Pacific region are projected to offer significant growth opportunities to the market players due to increasing cases of inherited diseases such as Down syndrome, colon (colorectal) cancer, and breast cancer, growing awareness about the significance of genetic tests, increasing healthcare expenditure, increasing government initiatives for promoting genetic tests, and growing investments by major market players.
This report provides pre & post COVID-19 market estimates.
1. Market Definition & Scope
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Declining Costs of Sequencing
4.2.2. Funding and Investments from Private & Public Organizations
4.2.3. Surge in Prevalence of Genetic Diseases
4.3. Restraints
4.3.1. Lack of Standardized Approaches in Genomics
4.3.2. Data Privacy Concerns Pertaining to Genomic Information
4.4. Opportunities
4.4.1. Rising Adoption of Personalized Medicines and Gene Therapy
4.5. Challenges
4.5.1. Shortage of Skilled Workforce in Bioinformatics and Genomics
4.5.2. Challenges Pertaining to the Commercialization and Scaling of Genomic Technologies
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Case Study
5. Global Genomics Market Assessment—by Offering
5.1. Overview
5.2. Systems
5.3. Consumables
5.4. Software & Services
6. Global Genomics Market Assessment—by Technology
6.1. Overview
6.2. Sequencing
6.2.1. NGS
6.2.2. Sanger Sequencing and Pyrosequencing
6.3. DNA Microarray
6.4. PCR
6.5. Nucleic Acid Extraction and Purification
6.6. Other Technologies
7. Global Genomics Market Assessment—by Application
7.1. Overview
7.2. Drug Discovery & Development
7.3. Diagnostics
7.4. Life Science Research
7.4.1. Stem Cell Research
7.4.2. Cancer Research
7.4.3. Other Life Science Research
7.5. Other Applications
8. Global Genomics Market Assessment—by End User
8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Hospitals
8.4. Academic & Research Institutes
8.5. Diagnostic Laboratories
8.6. Contract Research Organizations (CROs)
8.7. Other End Users
9. Genomics Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America (RoLATAM)
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Dashboard
10.3.1. Industry Leaders
10.3.2. Market Differentiators
10.3.3. Vanguards
10.3.4. Emerging Companies
10.4. Vendor Market Positioning
10.5. Market Share Analysis (2022)
11. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)
11.1. Agilent Technologies, Inc.
11.2. Pacific Biosciences of California, Inc.
11.3. Danaher Corporation
11.4. F. Hoffmann-La Roche Ltd
11.5. Bio-Rad Laboratories, Inc.
11.6. Thermo Fisher Scientific Inc.
11.7. Myriad Genetics, Inc.
11.8. Illumina, Inc.
11.9. Oxford Nanopore Technologies plc
11.10. New England Biolabs, Inc.
11.11. Promega Corporation
11.12. QIAGEN N.V.
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Global Genomics Market: Impact Analysis of Drivers (2023–2030)
Table 2 Global Genomics Market: Impact Analysis of Restraints (2023–2030)
Table 3 Global Genomics Market Opportunities: Impact Analysis of Opportunities (2023–2030)
Table 4 Global Genomics Market: Impact Analysis of Challenges (2023–2030)
Table 5 Global Genomics Market, by Offering, 2021–2030 (USD Million)
Table 6 Global Genomics Systems Market, by Country/Region, 2021–2030 (USD Million)
Table 7 Global Genomics Consumables Market, by Country/Region, 2021–2030 (USD Million)
Table 8 Global Genomics Software & Services Market, by Country/Region, 2021–2030 (USD Million)
Table 9 Global Genomics Market, by Technology, 2021–2030 (USD Million)
Table 10 Global Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 11 Global Genomics Market for Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 12 Global Genomics Market for NGS, by Country/Region, 2021–2030 (USD Million)
Table 13 Global Genomics Market for Sanger Sequencing and Pyrosequencing, by Country/Region, 2021–2030 (USD Million)
Table 14 Global Genomics Market for DNA Microarray, by Country/Region, 2021–2030 (USD Million)
Table 15 Global Genomics Market for PCR, by Country/Region, 2021–2030 (USD Million)
Table 16 Global Genomics Market for Nucleic Acid Extraction and Purification, by Country/Region, 2021–2030 (USD Million)
Table 17 Global Genomics Market for Other Technologies, by Country/Region, 2021–2030 (USD Million)
Table 18 Global Genomics Market, by Application, 2021–2030 (USD Million)
Table 19 Global Genomics Market for Drug Discovery & Development, by Country/Region, 2021–2030 (USD Million)
Table 20 Global Genomics Market for Diagnostics, by Country/Region, 2021–2030 (USD Million)
Table 21 Global Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 22 Global Genomics Market for Life Research, by Country/Region, 2021–2030 (USD Million)
Table 23 Global Genomics Market for Stem Cell Research, by Country/Region, 2021–2030 (USD Million)
Table 24 Global Genomics Market for Cancer Research, by Country/Region, 2021–2030 (USD Million)
Table 25 Global Genomics Market for Other Life Science Research, by Country/Region, 2021–2030 (USD Million)
Table 26 Global Genomics Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 27 Global Genomics Market, by End User, 2021–2030 (USD Million)
Table 28 Global Genomics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2021–2030 (USD Million)
Table 29 Global Genomics Market for Hospitals, by Country/Region, 2021–2030 (USD Million)
Table 30 Global Genomics Market for Academic & Research Institutes, by Country/Region, 2021–2030 (USD Million)
Table 31 Global Genomics Market for Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 32 Global Genomics Market for Contract Research Organizations (CROs), by Country/Region, 2021–2030 (USD Million)
Table 33 Global Genomics Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 34 Global Genomics Market, by Country/Region, 2021–2030 (USD Million)
Table 35 North America: Genomics Market, by Country, 2021–2030 (USD Million)
Table 36 North America: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 37 North America: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 38 North America: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 39 North America: Genomics Market, by Application, 2021–2030 (USD Million)
Table 40 North America: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 41 North America: Genomics Market, by End User, 2021–2030 (USD Million)
Table 42 U.S.: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 43 U.S.: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 44 U.S.: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 45 U.S.: Genomics Market, by Application, 2021–2030 (USD Million)
Table 46 U.S.: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 47 U.S.: Genomics Market, by End User, 2021–2030 (USD Million)
Table 48 Canada: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 49 Canada: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 50 Canada: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 51 Canada: Genomics Market, by Application, 2021–2030 (USD Million)
Table 52 Canada: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 53 Canada: Genomics Market, by End User, 2021–2030 (USD Million)
Table 54 Europe: Genomics Market, by Country/Region, 2021–2030 (USD Million)
Table 55 Europe: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 56 Europe: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 57 Europe: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 58 Europe: Genomics Market, by Application, 2021–2030 (USD Million)
Table 59 Europe: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 60 Europe: Genomics Market, by End User, 2021–2030 (USD Million)
Table 61 Germany: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 62 Germany: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 63 Germany: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 64 Germany: Genomics Market, by Application, 2021–2030 (USD Million)
Table 65 Germany: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 66 Germany: Genomics Market, by End User, 2021–2030 (USD Million)
Table 67 U.K.: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 68 U.K.: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 69 U.K.: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 70 U.K.: Genomics Market, by Application, 2021–2030 (USD Million)
Table 71 U.K.: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 72 U.K.: Genomics Market, by End User, 2021–2030 (USD Million)
Table 73 France: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 74 France: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 75 France: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 76 France: Genomics Market, by Application, 2021–2030 (USD Million)
Table 77 France: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 78 France: Genomics Market, by End User, 2021–2030 (USD Million)
Table 79 Italy: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 80 Italy: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 81 Italy: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 82 Italy: Genomics Market, by Application, 2021–2030 (USD Million)
Table 83 Italy: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 84 Italy: Genomics Market, by End User, 2021–2030 (USD Million)
Table 85 Spain: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 86 Spain: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 87 Spain: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 88 Spain: Genomics Market, by Application, 2021–2030 (USD Million)
Table 89 Spain: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 90 Spain: Genomics Market, by End User, 2021–2030 (USD Million)
Table 91 Rest of Europe: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 92 Rest of Europe: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 93 Rest of Europe: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 94 Rest of Europe: Genomics Market, by Application, 2021–2030 (USD Million)
Table 95 Rest of Europe: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 96 Rest of Europe: Genomics Market, by End User, 2021–2030 (USD Million)
Table 97 Asia-Pacific: Genomics Market, by Country/Region, 2021–2030 (USD Million)
Table 98 Asia-Pacific: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 99 Asia-Pacific: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 100 Asia-Pacific: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 101 Asia-Pacific: Genomics Market, by Application, 2021–2030 (USD Million)
Table 102 Asia-Pacific: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 103 Asia-Pacific: Genomics Market, by End User, 2021–2030 (USD Million)
Table 104 Japan: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 105 Japan: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 106 Japan: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 107 Japan: Genomics Market, by Application, 2021–2030 (USD Million)
Table 108 Japan: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 109 Japan: Genomics Market, by End User, 2021–2030 (USD Million)
Table 110 China: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 111 China: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 112 China: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 113 China: Genomics Market, by Application, 2021–2030 (USD Million)
Table 114 China: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 115 China: Genomics Market, by End User, 2021–2030 (USD Million)
Table 116 India: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 117 India: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 118 India: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 119 India: Genomics Market, by Application, 2021–2030 (USD Million)
Table 120 India: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 121 India: Genomics Market, by End User, 2021–2030 (USD Million)
Table 122 Rest of Asia-Pacific: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 123 Rest of Asia-Pacific: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 124 Rest of Asia-Pacific: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 125 Rest of Asia-Pacific: Genomics Market, by Application, 2021–2030 (USD Million)
Table 126 Rest of Asia-Pacific: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 127 Rest of Asia-Pacific: Genomics Market, by End User, 2021–2030 (USD Million)
Table 128 Latin America: Genomics Market, by Country/Region, 2021–2030 (USD Million)
Table 129 Latin America: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 130 Latin America: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 131 Latin America: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 132 Latin America: Genomics Market, by Application, 2021–2030 (USD Million)
Table 133 Latin America: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 134 Latin America: Genomics Market, by End User, 2021–2030 (USD Million)
Table 135 Brazil: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 136 Brazil: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 137 Brazil: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 138 Brazil: Genomics Market, by Application, 2021–2030 (USD Million)
Table 139 Brazil: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 140 Brazil: Genomics Market, by End User, 2021–2030 (USD Million)
Table 141 Mexico: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 142 Mexico: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 143 Mexico: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 144 Mexico: Genomics Market, by Application, 2021–2030 (USD Million)
Table 145 Mexico: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 146 Mexico: Genomics Market, by End User, 2021–2030 (USD Million)
Table 147 Rest of Latin America: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 148 Rest of Latin America: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 149 Rest of Latin America: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 150 Rest of Latin America: Genomics Market, by Application, 2021–2030 (USD Million)
Table 151 Rest of Latin America: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 152 Rest of Latin America: Genomics Market, by End User, 2021–2030 (USD Million)
Table 153 Middle East & Africa: Genomics Market, by Offering, 2021–2030 (USD Million)
Table 154 Middle East & Africa: Genomics Market, by Technology, 2021–2030 (USD Million)
Table 155 Middle East & Africa: Genomics Market for Sequencing, by Type, 2021–2030 (USD Million)
Table 156 Middle East & Africa: Genomics Market, by Application, 2021–2030 (USD Million)
Table 157 Middle East & Africa: Genomics Market for Life Science Research, by Type, 2021–2030 (USD Million)
Table 158 Middle East & Africa: Genomics Market, by End User, 2021–2030 (USD Million)
Table 159 Recent Developments, by Company (2020–2023)
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Estimation
Figure 7 Global Genomics Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 8 Global Genomics Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global Genomics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global Genomics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 11 Global Genomics Market, by Geography
Figure 12 Market Dynamics
Figure 13 Global Genomics Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 14 Global Genomics Market, by Technology, 2023 Vs. 2030 (USD Million)
Figure 15 Global Genomics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 16 Global Genomics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 17 Global Genomics Market, by Geography, 2023 Vs. 2030 (USD Million)
Figure 18 North America: Genomics Market Snapshot
Figure 19 Europe: Genomics Market Snapshot
Figure 20 Asia-Pacific: Genomics Market Snapshot
Figure 21 Latin America: Genomics Market Snapshot
Figure 22 Key Growth Strategies Adopted by Leading Players (2019–2023)
Figure 23 Genomics Market: Competitive Benchmarking, by Offering
Figure 24 Genomics Market: Competitive Benchmarking, by Technology
Figure 25 Competitive Dashboard: Genomics Market
Figure 26 Market Share Analysis: Genomics Market (2022)
Figure 27 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 28 Pacific Biosciences of California, Inc.: Financial Overview (2022)
Figure 29 Danaher Corporation: Financial Overview (2022)
Figure 30 F. Hoffmann-La Roche Ltd: Financial Overview (2022)
Figure 31 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
Figure 32 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 33 Myriad Genetics, Inc.: Financial Overview (2022)
Figure 34 Illumina, Inc.: Financial Overview (2022)
Figure 35 Oxford Nanopore Technologies plc: Financial Overview (2021)
Figure 36 QIAGEN N.V.: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2018
Published Date: Aug-2017
Published Date: Nov-2022
